Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACTS Esteban Pombo-Villar Chief Operating Officer Nicola Wootton ADDRESS 94a Milton Park Abingdon Oxfordshire OX14 4RY United Kingdom TELEPHONE +44 1235 861770 (Head Office) +41 (0)61 225 4290 (Direct) FAX +44 1235 861771 EMAIL epv@oxbt.co.uk nw@oxbt.co.uk YEAR FOUNDED 2004 Oxford BioTherapeutics Ltd www.oxbt.co.uk FINANCIAL SUMMARY Private COMPANY PROFILE Oxford BioTherapeutics (OBT) is focused on the development of targeted antibody-based medicines for oncology. OBT’s strategy is to develop innovative antibody-based cancer drugs, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP® proteomic database. Through its alliances with world leaders in antibody development OBT is in an unrivalled position to convert its novel targets into an exciting pipeline of first-in-class therapeutics for the treatment of cancer. OBT’s pipeline will deliver cost-effective medicines to fulfill the major unmet medical need of cancer patients. MANAGEMENT Christian Rohlff, CEO Esteban Pombo-Villar, COO Jon Terrett, CSO Tom Boone, Senior Vice President, Protein Sciences t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACTS Nick McCooke Chief Executive Officer Prof Nick La Thangue Chief Scientific Officer Prof David Kerr, Chief Medical Officer ADDRESS Magdalen Centre Oxford Science Park Oxford OX4 4GA TELEPHONE Office: +44 1865 784000 Mobile: +44 7900 214268 FAX +44 1235 861771 EMAIL nick.mccooke@oxfordbio.com YEAR FOUNDED 2011 Oxford Cancer Biomarkers www.oxfordbio.com FINANCIAL SUMMARY $5M funding via equity investment from Quintiles COMPANY PROFILE Oxford Cancer Biomarkers (OCB) is a newly launched company developing tests that predict which cancer patients will respond favorably to existing and emerging cancer drugs allowing treatment to be tailored to individual patients. The company, which is a spin out from Oxford University, has a patent-protected and validated platform for discovering proteins that are novel chemosensitivity markers for specific drugs. OCB is developing its biomarkers tests both independently and in partnership with pharma and biotech companies. Setting the company apart from the crowd, OCB has already implemented a strategic relationship with Quintiles Inc that provides a route for accelerating its novel biomarkers into clinical trials, overcoming the inertia that can sometimes hamper the companion biomarker business model. The company has secured initial funding via a $5 million equity investment from Quintiles. OCB’s management team, led by Nick McCooke, former CEO of Solexa (the pioneer of next gen sequencing) and Pronota (protein biomarker diagnostic development), includes David Kerr, Professor of Cancer Medicine at the University of Oxford and a recent President of the European Society of Medical Oncology, and Nick La Thangue, Professor of Cancer Biology at the University of Oxford. MANAGEMENT Nick McCooke, CEO Nick is the former CEO of Pronota (developer of diagnostics based on novel protein biomarkers) and Solexa (the pioneer of next gen sequencing). David Kerr, CMO David is Professor of Cancer Medicine at the University of Oxford and a recent President of the European Society of Medical Oncology. Nick La Thangue, CSO Nick is Professor of Cancer Biology at the University of Oxford. His academic research is focused on the molecular mechanisms that give rise to the abnormal proliferation of tumour cells. t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2:
B I O T E C H I N E U R O P E I N V
Page 3 and 4:
Events Diary For regular updates, s
Page 5 and 6:
Speakers Alexey Eliseev, Managing D
Page 7 and 8:
Speakers Blake M. Paterson, Co-Foun
Page 9 and 10:
Speakers David Slack, Head of Corpo
Page 11 and 12:
Speakers Frank Grams, VP, Head Alli
Page 13 and 14:
Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16:
Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18:
Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20:
Speakers Paul Higham, Managing Dire
Page 21 and 22:
Speakers Richard Goodfellow, CEO, S
Page 23 and 24:
Speakers Søren Moller, Managing In
Page 25 and 26:
CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55 and 56: CONTACT Martin Bonde, PhD, BComm Ch
Page 57 and 58: CONTACT Benedikt Timmerman Chief Ex
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77: CONTACTS Carlos Buesa Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100: CONTACTS Piers Morgan Chief Financi
Page 101 and 102: CONTACT Jakob Knudsen Chief Executi
Page 103 and 104: CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106: Supporting Organisations Citigate D
Page 107 and 108: Supporting Organisations Life Scien
Page 109 and 110: Supporting Organisations Swiss Biot
Page 111 and 112: Supporting Organisations Torreya Pa
Page 113: B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?